Abstract
In this study, we were concerned with the effect of probenecid on the pharmacokinetics of 1,000 mg of cefmenoxime administered over a 30-min period by intravenous infusion. Each of a total of 10 subjects received cefmenoxime twice, once with and once without adjunctive probenecid. The data were fit by iterative nonlinear regression procedures to a two-compartment open pharmacokinetic model, with elimination from the central compartment. The mean calculated peak concentration, area under the curve from zero to infinity, and half-life without probenecid were 78.1 micrograms/ml, 77.2 micrograms . h/ml, and 1.14 h, respectively. When cefmenoxime was administered with probenecid, these values were 86.7 micrograms/ml, 158.2 micrograms . h/ml, and 1.78 h, respectively. Averages of about 55 and 46% of the administered doses were recovered in urine samples collected at 0 through 24 h for doses administered without and with probenecid, respectively. The mean corrected renal drug clearance was 159 and 66 ml/min without and with probenecid, respectively. Statistical significance (P less than 0.05) was demonstrated for the differences in beta half-life, (K/net), calculated peak concentration, area under the curve from 0 to infinity, and renal clearance, but not for K21, K12, volume of distribution, or alpha-phase distribution rate constant. The results of this study indicate that tubular secretion is the predominant mechanism of clearance for cefmenoxime and that probenecid alters the pharmacokinetics of the compound by competitively inhibiting its tubular secretion without affecting either the rate or the extent of its distribution.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- BEYER K. H., WIEBELHAUS V. D., TILLSON E. K., RUSSO H. F., WILHOYTE K. M. 'Benemid', p-(di-n-propylsulfamyl)-benzoic acid: inhibition of glycine conjugative reactions. Proc Soc Exp Biol Med. 1950 Aug;74(4):772–775. doi: 10.3181/00379727-74-18043. [DOI] [PubMed] [Google Scholar]
- BOGER W. P., BEATTY J. O., PITTS F. W., FLIPPIN H. F. The influence of a new benzoic acid derivative on the metabolism of paraaminosalicylic acid (PAS) and penicillin. Ann Intern Med. 1950 Jul;33(1):18–31. doi: 10.7326/0003-4819-33-1-18. [DOI] [PubMed] [Google Scholar]
- BOGER W. P., PITTS F. W., GALLAGHER M. E. Benemid and carinamide: comparison of effect on para-aminosalicylic acid (PAS) plasma concentrations. J Lab Clin Med. 1950 Aug;36(2):276–282. [PubMed] [Google Scholar]
- Cunningham R. F., Israili Z. H., Dayton P. G. Clinical pharmacokinetics of probenecid. Clin Pharmacokinet. 1981 Mar-Apr;6(2):135–151. doi: 10.2165/00003088-198106020-00004. [DOI] [PubMed] [Google Scholar]
- DeSante K. A., Israel K. S., Brier G. L., Wolny J. D., Hatcher B. L. Effect of probenecid on the pharmacokinetics of moxalactam. Antimicrob Agents Chemother. 1982 Jan;21(1):58–61. doi: 10.1128/aac.21.1.58. [DOI] [PMC free article] [PubMed] [Google Scholar]
- GUTMAN A., YU T. F., SIROTA J. H. A study, by simultaneous clearance techniques, of salicylate excretion in man: effect of alkalinization of the urine by bicarbonate administration; effect of probenecid. J Clin Invest. 1955 May;34(5):711–721. doi: 10.1172/JCI103124. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Granneman G. R., Sennello L. T. A very precise high-performance liquid chromatographic procedure for the determination of cefmenoxime, a new cephalosporin antibiotic, in plasma. J Chromatogr. 1982 Apr 16;229(1):149–157. doi: 10.1016/s0378-4347(00)86046-6. [DOI] [PubMed] [Google Scholar]
- Jovanovich J. F., Saravolatz L. D., Burch K., Pohlod D. J. Failure of probenecid to alter the pharmacokinetics of ceforanide. Antimicrob Agents Chemother. 1981 Oct;20(4):530–532. doi: 10.1128/aac.20.4.530. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Talseth T., Haegele K. D., McNay J. L., Skrdlant H. B., Clementi W. A., Shepherd A. M. Pharmacokinetics and cardiovascular effects in rabbits of a major hydralazine metabolite, the hydralazine pyruvic-acid hydrazone. J Pharmacol Exp Ther. 1979 Dec;211(3):509–513. [PubMed] [Google Scholar]